Clinical trial
A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
NCT06362980
Study timeline
Study start (actual)2024-05-22Date precision: day
Registry last updated2024-07-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
NSCLCunresolved
Interventions
BPI-1178DRUG
OsimertinibDRUG · verified · RxNorm: osimertinib
Sponsors & collaborators
National Cancer Center, Chinalead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06362980 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.